Chronic obstructive pulmonary disease (COPD) Key Players – Axikin Pharmaceuticals In, Bayer AG,Beech Tree Labs Inc, Cytokinetics Inc and F. Hoffmann-La Roche Ltd Analysis and Forecast to 2022
Chronic obstructive pulmonary disease (COPD)
Overview
Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain.
The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2450254-chronic-obstructive-pulmonary-disease-copd-pipeline-review-h2-2017
Top Companies mentioned
Axikin Pharmaceuticals Inc
Bayer AG
Beech Tree Labs Inc
Cytokinetics Inc
Daiichi Sankyo Co Ltd
Errant Gene Therapeutics LLC
Hoffmann-La Roche Ltd
Galapagos NV
Humanigen Inc
iCeutica Inc
Major Highlight
Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 1, 13, 37, 23, 84, 23 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.
Chronic Obstructive Pulmonary Disease (COPD) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2450254-chronic-obstructive-pulmonary-disease-copd-pipeline-review-h2-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by
Vivian Dsena
on Wednesday February 14 2018, 6:08 AM EST.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
